Bogdan Zalewski1. 1. 2nd Department of General and Gastroenterological Surgery, Medical University of Bialystok, M. Sklodowskiej-Curie st. 24a, 15-276 Bialystok, Poland. bogdan-zalewski@wp.pl
Abstract
AIM: This study was designed to compare the levels of v5 and v6 splice variants of CD44 evaluated using ELISA test in the serum of patients with colorectal cancer in different stages of progression of the disease estimated in pT stage according to WHO score, histopathological grade of malignancy and some clinicopathological features. METHODS: The serum obtained from 114 persons with colorectal adenocarcinomas was examined using ELISA method. pT stage and grade of malignancy of the tumour were examined in formalin fixed and paraffin embedded materials obtained during operation. RESULTS: Only the level of CD44 v5 in the serum of patients before operation with G2 pT4 tumour was lower than that in other probes and the difference was statistically significant. We did not find any other correlations between the level of v5 and v6 CD44 variants and other evaluated parameters. CONCLUSION: The level of CD44 v5 and v6 estimated by ELISA test in the serum can not be used as a prognostic factor in colorectal cancer.
AIM: This study was designed to compare the levels of v5 and v6 splice variants of CD44 evaluated using ELISA test in the serum of patients with colorectal cancer in different stages of progression of the disease estimated in pT stage according to WHO score, histopathological grade of malignancy and some clinicopathological features. METHODS: The serum obtained from 114 persons with colorectal adenocarcinomas was examined using ELISA method. pT stage and grade of malignancy of the tumour were examined in formalin fixed and paraffin embedded materials obtained during operation. RESULTS: Only the level of CD44 v5 in the serum of patients before operation with G2 pT4 tumour was lower than that in other probes and the difference was statistically significant. We did not find any other correlations between the level of v5 and v6 CD44 variants and other evaluated parameters. CONCLUSION: The level of CD44 v5 and v6 estimated by ELISA test in the serum can not be used as a prognostic factor in colorectal cancer.
Authors: T Fujisaki; Y Tanaka; K Fujii; S Mine; K Saito; S Yamada; U Yamashita; T Irimura; S Eto Journal: Cancer Res Date: 1999-09-01 Impact factor: 12.701
Authors: Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun Journal: CA Cancer J Clin Date: 2003 Jan-Feb Impact factor: 508.702
Authors: A Llaneza; A Gonzalez; A Andicoechea; J C Fernandez; M T Allende; J L García-Muñiz; F Vizoso Journal: Int J Biol Markers Date: 2000 Apr-Jun Impact factor: 3.248
Authors: Zahra Amirghofran; Seyed Amir Jalali; Seyed Vahid Hosseini; Mohammad Vasei; Behnam Sabayan; Abbas Ghaderi Journal: J Gastrointest Cancer Date: 2009-03-31
Authors: Balázs Bánky; Lívia Rásó-Barnett; Tamás Barbai; József Tímár; Péter Becságh; Erzsébet Rásó Journal: Mol Cancer Date: 2012-11-14 Impact factor: 27.401